

**In the Specification:**

Please amend the specification as shown:

Please delete the paragraph on page 2, line 26 to page 3, line 10 and replace it with the following paragraph:

The present invention thus provides the use, in the preparation of medicines of the medicines having activity of the antihypertensive type, useful for treating or preventing hypertension, of one or more peptides having inhibiting activity on ACE with IC<sub>50</sub> values of the order of or less than 60 millimolar ( $\mu$ m), selected from the group of peptides having the following amino acid sequences:

Thr-Val-Tyr (SEQ ID NO: 1),

1

Asn-Met-Ala-Ile-Asn-Pro-Ser-Lys (SEQ ID NO: 2),

1

5

Phe-Ala-Leu-Pro-Gln-Tyr (SEQ ID NO: 3),

1

5

Phe-Pro-Gln-Tyr-Leu-Gln-Tyr (SEQ ID NO: 4),

1

5

Phe-Ala-Leu-Pro-Gln-Tyr-Leu-Lys (SEQ ID NO: 5),

1

5

Asn-Met-Ala-Ile-Asn-Pro (SEQ ID NO: 6),

1

5

Phe-Ala-Leu-Pro (SEQ ID NO: 7).

1

Please delete the paragraph on page 3, lines 32-34 and replace it with the following paragraph:

the peptide Phe-Ala-Leu-Pro-Gln-Tyr, [FALPQY (SEQ ID No. 3)] of molecular weight 737.9 corresponds to the 174-179 peptide of  $\alpha_{s2}$  casein;

Please delete the paragraph on page 11, lines 27-29 and replace it with the following paragraph:

(SEQ ID No. 8), CN $\alpha$ <sub>S2</sub> -(f81-89), ALNEINQFY, Ala-Leu-Asn-Glu-Ile-Asn-Gln-Phe-~~Try~~Tyr-Gln-Lys, peak 5 eluted at 52 min;